Research programme: long-acting injectable therapies - Neuraxpharm Group/Pharmathen
Latest Information Update: 28 Feb 2025
At a glance
- Originator Neuraxpharm; Pharmathen
- Class Antipsychotics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Psychiatric disorders